Shandong Xinhua Pharmaceutical Terminates Equity Acquisition Talks With NovoSana

MT Newswires Live02-09 10:43

Shandong Xinhua Pharmaceutical (HKG:0719) has terminated an equity acquisition intention agreement with NovoSana (Europe) after the parties failed to reach consensus on the terms of a formal agreement, according to a Friday Hong Kong bourse filing.

The agreement, announced in December 2024, contemplated a potential acquisition of up to 75% equity interest in NovoSana (Taicang), which would have become a holding subsidiary of the company upon completion.

The proposed transaction was intended to support Shandong Xinhua's expansion into the fish oil sector.

Shandong Xinhua said the termination will not affect its current production or operations and will not have any adverse impact on the company's development or shareholders' interests.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2610502696?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-09 10:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610502696","market":"hk","top_or_hot":-1,"title":"Shandong Xinhua Pharmaceutical Terminates Equity Acquisition Talks With NovoSana","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/SXPHF\">Shandong Xinhua</a> Pharmaceutical (HKG:0719) has terminated an equity acquisition intention agreement with NovoSana (Europe) after the parties failed to reach consensus on the terms of a formal agreement, according to a Friday Hong Kong bourse filing.</p><p>The agreement, announced in December 2024, contemplated a potential acquisition of up to 75% equity interest in NovoSana (Taicang), which would have become a holding subsidiary of the company upon completion.</p><p>The proposed transaction was intended to support <a href=\"https://laohu8.com/S/000756\">Shandong Xinhua</a>'s expansion into the fish oil sector.</p><p><a href=\"https://laohu8.com/S/00719\">Shandong Xinhua</a> said the termination will not affect its current production or operations and will not have any adverse impact on the company's development or shareholders' interests.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shandong Xinhua Pharmaceutical Terminates Equity Acquisition Talks With NovoSana</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShandong Xinhua Pharmaceutical Terminates Equity Acquisition Talks With NovoSana\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-02-09 10:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/SXPHF\">Shandong Xinhua</a> Pharmaceutical (HKG:0719) has terminated an equity acquisition intention agreement with NovoSana (Europe) after the parties failed to reach consensus on the terms of a formal agreement, according to a Friday Hong Kong bourse filing.</p><p>The agreement, announced in December 2024, contemplated a potential acquisition of up to 75% equity interest in NovoSana (Taicang), which would have become a holding subsidiary of the company upon completion.</p><p>The proposed transaction was intended to support <a href=\"https://laohu8.com/S/000756\">Shandong Xinhua</a>'s expansion into the fish oil sector.</p><p><a href=\"https://laohu8.com/S/00719\">Shandong Xinhua</a> said the termination will not affect its current production or operations and will not have any adverse impact on the company's development or shareholders' interests.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2610502696","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610502696","pubTimestamp":1770605005,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Shandong Xinhua Pharmaceutical  has terminated an equity acquisition intention agreement with NovoSana  after the parties failed to reach consensus on the terms of a formal agreement, according to a Friday Hong Kong bourse filing.The agreement, announced in December 2024, contemplated a potential acquisition of up to 75% equity interest in NovoSana , which would have become a holding subsidiary of the company upon completion.The proposed transaction was intended to support Shandong Xinhua's expansion into the fish oil sector.Shandong Xinhua said the termination will not affect its current production or operations and will not have any adverse impact on the company's development or shareholders' interests.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK1515":"抗疫概念","BK4588":"碎股","BK1191":"制药","000756":"新华制药","00719":"山东新华制药股份","BK4215":"住宅房地产投资信托","BK0239":"医药制造","BK0164":"国企混改","EQR":"资产住宅公司"},"translate_title":"山东新华制药终止与NovoSana股权收购谈判","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EQR":1.5,"00719":0.9,"000756":0.9},"content_text":"Shandong Xinhua Pharmaceutical (HKG:0719) has terminated an equity acquisition intention agreement with NovoSana (Europe) after the parties failed to reach consensus on the terms of a formal agreement, according to a Friday Hong Kong bourse filing.The agreement, announced in December 2024, contemplated a potential acquisition of up to 75% equity interest in NovoSana (Taicang), which would have become a holding subsidiary of the company upon completion.The proposed transaction was intended to support Shandong Xinhua's expansion into the fish oil sector.Shandong Xinhua said the termination will not affect its current production or operations and will not have any adverse impact on the company's development or shareholders' interests.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2610502696","isCrawlerRequest":true}